Skip directly to site content Skip directly to search


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tickborne Diseases of the United States


Facebook
        Twitter
        LinkedIn
        Syndicate





Tickborne Diseases Abroad					minus icon
                Contents
			HomeTick IDOverview of Tickborne DiseasesLyme DiseaseTickborne Relapsing Fever (TBRF)Hard Tick Relapsing FeverAnaplasmosisEhrlichiosisRocky Mountain Spotted FeverRickettsia parkeri RickettsiosisTularemiaBabesiosisHeartland and Bourbon Virus DiseasesColorado Tick FeverPowassan Virus DiseaseTickborne Diseases AbroadTick Bites/PreventionLyme Disease Prophylaxis After Tick Bite					Related Pages
										African Tick Bite Fever (ATBF)Agent*Rickettsia africae*African tick bite fever (ATBF) is the most commonly diagnosed rickettsial disease among returning international travelers. ATBF is transmitted by *Amblyomma hebraeum* and *A. variegatum* ticks. Travel-associated cases of ATBF often occur in clusters with exposure during activities such as safari tours, game hunting, and bush hiking.Where FoundSub-Saharan Africa, Caribbean (French West Indies), and OceaniaIncubation PeriodTypically 5–7 days but may be as long as 10 daysSigns and SymptomsATBF is typically a mild-to-moderate disease; no known deaths are attributable to infection with *R. africae*. ATBF is almost always associated with an inoculation eschar (see *R. parkeri* rickettsiosis) at the site of tick attachment. Multiple eschars are described in approximately 20–50% of patients with ATBF. Several days after eschar(s) appear, the following can develop:
Fever
Headache
Myalgia
Regional lymphadenopathy
Rash (generalized with maculopapular or vesicular eruptions)General Laboratory FindingsSimilar to other *Rickettsia*, see *R. parkeri* rickettsiosis.Laboratory DiagnosisConfirmation of the diagnosis is based on laboratory testing, but antibiotic treatment should not be delayed pending laboratory confirmation.
ATBF can be confirmed using IFA or detection of Rickettsial DNA by PCR of eschar swab, skin biopsy, or whole blood. See *R.parkeri* rickettsiosis.
ATBF can be confirmed by comparing acute and convalescent (taken 4–6 weeks following illness onset) samples for evidence of seroconversion in IgG antibodies.TreatmentSee RMSF treatment.Lyme Disease (Europe and Asia)Agents*Borrelia afzelii, B. garinii, B. burgdorferi*sensu stricto, and*B. bavariensis*(previously considered a variant of *B. garinii*)Outside North America, *Borrelia* spp. that cause Lyme disease are transmitted through the bite of infected *Ixodes ricinus* and *I. persulcatus* ticks.Where FoundIn Europe, Lyme disease is endemic from southern Scandinavia into the northern Mediterranean countries of Italy, Spain, Portugal, and Greece and east from the British Isles into central Russia. Incidence is highest in Central and Eastern European countries. In Asia, infected ticks occur from western Russia through Mongolia, northeastern China, and Japan; however, human infection appears to be uncommon in some of these areas.Incubation Period3–30 daysSigns and SymptomsOutside of North America, most infections are caused by *B. afzelii, B. garinii*, *B. burgdorferi* sensu stricto, and *B. bavariensis* (previously considered a variant of *B. garinii*), with each causing somewhat different clinical manifestations.
As in the United States, the erythema migrans (EM) rash is the most common early manifestation; later neurologic, cardiac, and rheumatologic disease may occur. In European Lyme disease, the EM rash may spread more slowly and is less commonly accompanied by systemic symptoms. Atrophic skin lesions (acrodermatitis chronica atrophicans) are a frequent late manifestation of infection with *B. afzelii*. In Lyme disease caused by *B. garinii*, some individuals may develop Bannwarth syndrome, a severe neuroborreliosis characterized by radiculopathy, neuropathy, and lymphocytic meningitis.Laboratory ConfirmationAntibodies to *Borrelia* species that cause Lyme disease outside the United States may not be reliably detected by all tests used in the United States. Providers who suspect internationally-acquired Lyme disease should use diagnostic tests that have been validated for these species.TreatmentSee Lyme disease treatment.ReferencesSteere AC, Strle F, Wormser GP, et al. Lyme borreliosis. *Nat Rev Dis Primers*. 2016;2:16090.
Stone BL, Tourand Y, Brissette CA. Brave new worlds: The expanding universe of Lyme disease. *Vector Borne Zoonotic Dis*. 2017;17(9):619-629.
Vandekerckhove O, De Buck E, Van Wijngaerden E. Lyme disease in Western Europe: an emerging problem? A systematic review. *Acta Clin Belg*. 2021;76(3):244-252.Tickborne Encephalitis (TBE)AgentTick-borne encephalitis virusTBE is transmitted through the bite of infected *Ixodes ricinus* and *I. persulcatus* ticks.Where FoundEndemic in focal areas of Europe and Asia, extending from western and northern Europe through to northern and eastern Asia. The highest disease incidence has been reported from the Baltic states, Slovenia, and Czech Republic. Asian countries with reported cases or virus activity include China, Japan, Kazakhstan, Kyrgyzstan, Mongolia, and South Korea. TBE may also be acquired by ingestion of unpasteurized dairy products from infected goats, sheep, or cows.Incubation Period8 days (range, 4–28 days)Signs and SymptomsTBE disease often presents with mild illness but can cause neuroinvasive disease (i.e., aseptic meningitis, encephalitis). The course of illness can be monophasic or biphasic. If biphasic, the two phases are:
First phase: nonspecific febrile illness with headache, myalgia, and fatigue. Usually lasts for several days and may be followed by an afebrile and relatively asymptomatic period.
Second phase: central nervous system involvement. Findings depend on the specific presentation but might include meningeal signs, altered mental status, cognitive dysfunction, ataxia, rigidity, seizures, tremors, cranial nerve palsies, and limb paresis.Laboratory ConfirmationDuring the first phase of the illness, TBE virus or viral RNA can sometimes be detected in serum samples by virus isolation or RT-PCR. However, by the time neurologic symptoms are recognized, the virus or viral RNA is usually undetectable. Therefore, virus isolation and RT-PCR should not be used to rule out a diagnosis of TBE. Clinicians should contact their state or local health department or CDC’s Division of Vector-Borne Diseases (970-221-6400) for assistance with diagnostic testing.TreatmentThere is no specific antiviral treatment for TBE; therapy consists of supportive care and management of complications.PreventionInactivated TBE vaccine (manufactured as TICOVAC) is licensed and available in the United States. This vaccine is approved for use in people aged 1 years and older and is administered as a three-dose series.
TBE vaccine is recommended for persons who are moving or traveling to a TBE-endemic area and will have extensive exposure to ticks based on their planned outdoor activities and itinerary. In addition, TBE vaccine may be considered for persons traveling or moving to a TBE-endemic area who might engage in outdoor activities in areas ticks are likely to be found.Additional Travel-Associated Tickborne InfectionsDiseases and Geographic Location
DISEASE & ETIOLOGIC AGENT(S)
GEOGRAPHIC LOCATION AND ADDITIONAL RISK FACTORSMediterranean spotted fever (also
known as boutonneuse fever)
Europe (Mediterranean basin), Middle East, Indian subcontinent,
and Africa. Caused by *Rickettsia conorii*, symptoms include fever,
headache, muscle pain, eschar (usually single), and rash. It is
typically a moderately severe illness, and can be fatal.Crimean-Congo hemorrhagic fever*CCHF virus*
Asia, Africa, and Europe. May also be acquired by contact with
infected blood or saliva or inhalation of infected aerosols.Omsk hemorrhagic fever*Omsk hemorrhagic fever virus*
Southwestern Russia. May also be acquired by direct contact with
infected muskrats.Kyasanur Forest disease
Southern India, Saudi Arabia (aka Alkhurma disease in Saudi
Arabia). Typically associated with exposure while harvesting forest
products.ReferencesCenters for Disease Control and Prevention. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis—United States: a practical guide for health care and public health professionals. *MMWR* 2016;65 (No.RR-2).
Centers for Disease Control and Prevention. Brunette GW, Kozarsky PE, Cohen NJ, et al. *CDC Health Information for International Travel 2016 (Yellow Book)*. New York, NY: Oxford University Press; 2016.
European Centre for Disease Prevention and Control, Tick-borne diseases.
Fournier PE, Jensenius M, Laferl H, et al. Kinetics of antibody responses in *Rickettsia africae* and *Rickettsia conorii* infections. *Clin Diag Lab Immunol* 2002;9(2):324-328.
Goodman JL, Dennis DT, Sonenshine DE, editors. Tick-borne diseases of humans. Washington, DC: ASM Press; 2005.
Jensenius M, Fournier PE, Kelly P, et al. African tick bite fever. *Lancet Infect Dis* 2003;3(9):557-564.
Parola P, Paddock CD, Socolovschi C, et al. Update on tick-borne rickettsioses around the world: a geographic approach. *Clin Microbiol Rev* 2013;26(4):657-702.Top of Page
									PrevPowassan Virus Di...
			NextTick Bites/Preven...
							
					
						Page last reviewed:  August 5, 2022					Content source: 	Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD) homeTickborne Diseases of the United StatesTick IDOverview of Tickborne DiseasesLyme DiseaseTickborne Relapsing Fever (TBRF)Hard Tick Relapsing FeverAnaplasmosisEhrlichiosisRocky Mountain Spotted Fever*Rickettsia parkeri*RickettsiosisTularemiaBabesiosisHeartland and Bourbon Virus DiseasesColorado Tick FeverPowassan Virus DiseaseTickborne Diseases AbroadTick Bites/PreventionLyme Disease Prophylaxis After Tick Bite


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue